Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma.
[1][2][3][4][5] Retifanlimab is indicated for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
[1][2][6] The US Food and Drug Administration (FDA) evaluated the safety and efficacy of retifanlimab based on PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 participants with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease.
[2] The FDA granted the application for retifanlimab priority review, fast track, and orphan drug designations.
[7] The applicant for this medicinal product is Incyte Biosciences Distribution B.V.[7] Retifanlimab is the international nonproprietary name.